deferoxamine and Cerebral Hemorrhage studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Cerebral Hemorrhage: Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.

Research Excerpts

Excerpt	Relevance	Reference
"It has been shown that 3 days of 62 mg/kg/day deferoxamine infusion (maximum dose not to exceed 6000 mg/day) is safe and tolerated by intracerebral hemorrhage (ICH) patients."	9.20	The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. ( Gao, X; Kong, Z; Liu, G; Xu, Y; Yu, Y; Zhao, W; Zhu, C, 2015)
"Treatment with the iron chelator, deferoxamine mesylate (DFO), improves neurological recovery in animal models of intracerebral hemorrhage (ICH)."	9.15	Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. ( Goldstein, JN; Gomes, J; Greenberg, S; Morgenstern, LB; Palesch, Y; Schlaug, G; Selim, M; Torbey, M; Waldman, B; Xi, G; Yeatts, S, 2011)
" Iron chelation and iron overload was achieved by deferoxamine mesylate or iron dextran injection."	8.02	Iron chelation suppresses secondary bleeding after intracerebral hemorrhage in angiotensin II-infused mice. ( Chen, WX; Feng, H; Ge, HF; Guo, C; Li, CC; Tang, XQ; Wang, B; Wang, J; Xia, M; Yin, Y, 2021)
"To investigate the effects of the iron chelatordeferoxamine (DFA) on inhibition formicroglia activation and protection of secondary nerve injury after intracerebral hemorrhage (ICH) in rats."	7.83	The effects of deferoxamine on inhibition for microglia activation and protection of secondary nerve injury after intracerebral hemorrhage in rats. ( Jiang, L; Sun, YM; Wang, YT; Xue, MZ, 2016)
"Deferoxamine reduces neuronal death in a piglet model of intracerebral hemorrhage (ICH)."	7.80	Deferoxamine attenuates white matter injury in a piglet intracerebral hemorrhage model. ( Gu, Y; Hua, Y; Keep, RF; Liu, W; Xi, G; Xie, Q, 2014)
"To investigate the effect of the iron chelator deferoxamine (DFA) in suppressing microglia activation and protecting against secondary neural injury in a rat model of intracerebral hemorrhage (ICH)."	7.78	[Deferoxamine suppresses microglia activation and protects against secondary neural injury after intracerebral hemorrhage in rats]. ( Chen, X; Huang, W; Liu, X; Miao, X; Qiu, N; Wang, J; Xu, Y; Yang, J; Yue, Q; Zhang, Y, 2012)
"Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade."	7.78	Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012)
"Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats."	7.76	Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010)
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats."	7.75	Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009)
"In this study, we examine the effects of deferoxamine on hemoglobin-induced brain swelling in a newly developed hippocampal model of intracerebral hemorrhage (ICH)."	7.74	Deferoxamine reduces brain swelling in a rat model of hippocampal intracerebral hemorrhage. ( He, Y; Hua, Y; Keep, RF; Song, S; Wang, J; Wu, J; Xi, G, 2008)
" The effects of deferoxamine on ICH-induced brain injury were examined by measuring brain edema and neurological deficits."	7.72	Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. ( Hoff, JT; Hua, Y; Keep, RF; Nakamura, T; Schallert, T; Xi, G, 2003)
" The effects of deferoxamine on ICH-induced brain injury were examined by measuring brain edema and neurological deficits."	7.72	Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. ( Hoff, JT; Hua, Y; Keep, RF; Nakamura, T; Schallert, T; Xi, G, 2004)
"The i-DEF trial (Intracerebral Hemorrhage Deferoxamine Trial) assessed modified Rankin Scale (mRS) longitudinally at prespecified time points from day 7 through the end of the 6-month follow-up period."	7.11	Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial. ( Conwit, RA; Foster, L; Lioutas, V; Robinson, L; Selim, M; Shehadah, A; Yeatts, SD, 2022)
" Herein, we discuss the various dosing regimens and formulations employed in intranasal (IN) or systemic DFO treatment, as well as the physiological and behavioral outcomes observed in animal models of AD, PD, and ICH."	6.72	Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. ( Farr, AC; Xiong, MP, 2021)
"Patients for this analysis were selected from a previously completed multicenter, randomized, double-blind futility design clinical trial, the Intracerebral Hemorrhage Deferoxamine trial, and underwent a retrospective review of prospectively collected data."	5.51	Predicting Gastrostomy Tube Placement After Intracerebral Hemorrhage: External Validation of the GRAVo Score. ( Bhanu, G; Carvalho, F; Hasan, S; Heistand, E; Kumar, S; Lin, D; Marchina, S; Minyetty, M; Selim, M, 2022)
"Deferoxamine treatment has different effects on the expression of HSP-27 and HSP-32."	5.37	Deferoxamine affects heat shock protein expression in heart after intracerebral hemorrhage in aged rats. ( Hu, H; Hua, Y; Keep, RF; Okauchi, M; Wang, L; Xi, G, 2011)
"Iron overload occurs in brain after intracerebral hemorrhage (ICH)."	5.33	Deferoxamine reduces CSF free iron levels following intracerebral hemorrhage. ( Hoff, JT; Hua, Y; Keep, RF; Wan, S; Xi, G, 2006)
"It has been shown that 3 days of 62 mg/kg/day deferoxamine infusion (maximum dose not to exceed 6000 mg/day) is safe and tolerated by intracerebral hemorrhage (ICH) patients."	5.20	The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. ( Gao, X; Kong, Z; Liu, G; Xu, Y; Yu, Y; Zhao, W; Zhu, C, 2015)
"Treatment with the iron chelator, deferoxamine mesylate (DFO), improves neurological recovery in animal models of intracerebral hemorrhage (ICH)."	5.15	Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. ( Goldstein, JN; Gomes, J; Greenberg, S; Morgenstern, LB; Palesch, Y; Schlaug, G; Selim, M; Torbey, M; Waldman, B; Xi, G; Yeatts, S, 2011)
" Iron chelation (deferoxamine) is in clinical trial for intracerebral hemorrhage and preclinical data suggest it may be a potential treatment for IVH."	4.95	Challenges for intraventricular hemorrhage research and emerging therapeutic targets. ( Garton, T; Hua, Y; Keep, RF; Xi, G; Xiang, J, 2017)
" Iron chelation and iron overload was achieved by deferoxamine mesylate or iron dextran injection."	4.02	Iron chelation suppresses secondary bleeding after intracerebral hemorrhage in angiotensin II-infused mice. ( Chen, WX; Feng, H; Ge, HF; Guo, C; Li, CC; Tang, XQ; Wang, B; Wang, J; Xia, M; Yin, Y, 2021)
" Although deferoxamine (DFO) has been widely utilized as a clinical first-line siderophore to remove the iron overload, the ROS-inducing damage still greatly limits the therapeutic effect of DFO."	4.02	Efficient Iron and ROS Nanoscavengers for Brain Protection after Intracerebral Hemorrhage. ( Gu, Z; Li, Y; Tian, M; Wang, Y; Wei, Y; Yang, P; You, C; Zhong, R; Zhu, F; Zi, L, 2021)
" Deferoxamine (DFX), a metal chelator, removes iron overload and protects against brain damage in intracranial hemorrhage."	3.83	Deferoxamine inhibits microglial activation, attenuates blood-brain barrier disruption, rescues dendritic damage, and improves spatial memory in a mouse model of microhemorrhages. ( He, XF; Lan, Y; Liang, FY; Liu, DX; Pei, Z; Wang, Q; Xu, GQ; Zeng, JS; Zhang, Q, 2016)
"To investigate the effects of the iron chelatordeferoxamine (DFA) on inhibition formicroglia activation and protection of secondary nerve injury after intracerebral hemorrhage (ICH) in rats."	3.83	The effects of deferoxamine on inhibition for microglia activation and protection of secondary nerve injury after intracerebral hemorrhage in rats. ( Jiang, L; Sun, YM; Wang, YT; Xue, MZ, 2016)
"Deferoxamine reduces neuronal death in a piglet model of intracerebral hemorrhage (ICH)."	3.80	Deferoxamine attenuates white matter injury in a piglet intracerebral hemorrhage model. ( Gu, Y; Hua, Y; Keep, RF; Liu, W; Xi, G; Xie, Q, 2014)
"Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade."	3.78	Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012)
"To investigate the effect of the iron chelator deferoxamine (DFA) in suppressing microglia activation and protecting against secondary neural injury in a rat model of intracerebral hemorrhage (ICH)."	3.78	[Deferoxamine suppresses microglia activation and protects against secondary neural injury after intracerebral hemorrhage in rats]. ( Chen, X; Huang, W; Liu, X; Miao, X; Qiu, N; Wang, J; Xu, Y; Yang, J; Yue, Q; Zhang, Y, 2012)
" Deferoxamine may be a therapy for patients with IVH or intraventricular extension after intracerebral hemorrhage."	3.77	Role of iron in brain injury after intraventricular hemorrhage. ( Chen, Z; Gao, C; Hua, Y; Keep, RF; Muraszko, K; Xi, G, 2011)
"Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats."	3.76	Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010)
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats."	3.75	Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009)
"In this study, we examine the effects of deferoxamine on hemoglobin-induced brain swelling in a newly developed hippocampal model of intracerebral hemorrhage (ICH)."	3.74	Deferoxamine reduces brain swelling in a rat model of hippocampal intracerebral hemorrhage. ( He, Y; Hua, Y; Keep, RF; Song, S; Wang, J; Wu, J; Xi, G, 2008)
" The effects of deferoxamine on ICH-induced brain injury were examined by measuring brain edema and neurological deficits."	3.72	Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. ( Hoff, JT; Hua, Y; Keep, RF; Nakamura, T; Schallert, T; Xi, G, 2004)
" The effects of deferoxamine on ICH-induced brain injury were examined by measuring brain edema and neurological deficits."	3.72	Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. ( Hoff, JT; Hua, Y; Keep, RF; Nakamura, T; Schallert, T; Xi, G, 2003)
" The effects of an HO inhibitor, tin-protoporphyrin (SnPP), and the iron chelator deferoxamine, on hemoglobin-induced brain edema were also examined."	3.71	Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. ( Hoff, JT; Hua, Y; Huang, FP; Keep, RF; Nemoianu, A; Xi, G, 2002)
"The i-DEF trial (Intracerebral Hemorrhage Deferoxamine Trial) assessed modified Rankin Scale (mRS) longitudinally at prespecified time points from day 7 through the end of the 6-month follow-up period."	3.11	Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial. ( Conwit, RA; Foster, L; Lioutas, V; Robinson, L; Selim, M; Shehadah, A; Yeatts, SD, 2022)
"Deferoxamine mesylate was safe."	2.90	Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. ( Clark, WM; Foster, LD; Greenberg, SM; Hill, MD; James, ML; Morgenstern, LB; Moy, CS; Norton, C; Palesch, YY; Selim, M; Singh, V; Xi, G; Yeatts, SD, 2019)
" Herein, we discuss the various dosing regimens and formulations employed in intranasal (IN) or systemic DFO treatment, as well as the physiological and behavioral outcomes observed in animal models of AD, PD, and ICH."	2.72	Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. ( Farr, AC; Xiong, MP, 2021)
"Spontaneous intracerebral hemorrhage (SICH) continues to be a significant cause of neurologic morbidity and mortality throughout the world."	2.53	Treatment Strategies to Attenuate Perihematomal Edema in Patients With Intracerebral Hemorrhage. ( Chang, TR; Choi, HA; Edwards, NJ; Jo, KW; Kim, H; Lee, K, 2016)
"Deferoxamine was administered intraperitoneally for 3 consecutive days after GMH/iron trichloride."	1.48	Targeting Germinal Matrix Hemorrhage-Induced Overexpression of Sodium-Coupled Bicarbonate Exchanger Reduces Posthemorrhagic Hydrocephalus Formation in Neonatal Rats. ( Ding, Y; Krafft, P; Li, Q; Wan, W; Wu, G; Yan, F; Zhan, Q; Zhang, JH; Zhang, Y, 2018)
"Deferoxamine treatment attenuated ICH-induced CD163 upregulation and significantly reduced both brain CD163 and hemoglobin levels at day 3."	1.46	CD163 Expression in Neurons After Experimental Intracerebral Hemorrhage. ( Cao, S; Hua, Y; Huang, Y; Keep, RF; Liu, R; Xi, G, 2017)
"Post-hemorrhagic chronic hydrocephalus (PHCH) is a common complication after intraventricular hemorrhage (IVH)."	1.42	Deferoxamine alleviates chronic hydrocephalus after intraventricular hemorrhage through iron chelation and Wnt1/Wnt3a inhibition. ( Feng, H; Gong, G; Hu, R; Hu, S; Li, F; Meng, H; Yuan, Y, 2015)
"The pathogenesis of posthemorrhagic hydrocephalus is not fully understood."	1.40	Role of hemoglobin and iron in hydrocephalus after neonatal intraventricular hemorrhage. ( Bazzi, AA; Garton, HJ; Garton, T; Keep, RF; Kilaru, H; Maher, CO; Muraszko, KM; Strahle, JM; Xi, G, 2014)
"The role of CD47 in intracerebral hemorrhage (ICH) has not been investigated and the current study examined brain CD47 expression in a pig ICH model."	1.40	Brain CD47 expression in a swine model of intracerebral hemorrhage. ( Hua, Y; Keep, RF; Xi, G; Xie, Q; Zhou, X, 2014)
"Intracerebral hemorrhage was induced by intrastriatal injection of collagenase."	1.37	Iron toxicity in mice with collagenase-induced intracerebral hemorrhage. ( Wang, J; Wu, H; Wu, T; Xu, X, 2011)
"Deferoxamine treatment reduced the perihematomal reddish zone, and the number of Perls' (p<0."	1.37	Iron accumulation and DNA damage in a pig model of intracerebral hemorrhage. ( Gu, Y; He, Y; Hu, H; Hua, Y; Keep, RF; Wang, L; Xi, G, 2011)
"Deferoxamine treatment has different effects on the expression of HSP-27 and HSP-32."	1.37	Deferoxamine affects heat shock protein expression in heart after intracerebral hemorrhage in aged rats. ( Hu, H; Hua, Y; Keep, RF; Okauchi, M; Wang, L; Xi, G, 2011)
"Brain edema induced by intracerebral hemorrhage (ICH) is a serious problem in the treatment of ICH."	1.35	Poly(ADP-ribose) polymerase activation and brain edema formation by hemoglobin after intracerebral hemorrhage in rats. ( Bao, X; Hu, S; Huang, F; Wu, G, 2008)
"Brain edema formation following intracerebral hemorrhage (ICH) appears to be partly related to erythrocyte lysis and hemoglobin release."	1.35	Brain edema after intracerebral hemorrhage in rats: the role of iron overload and aquaporin 4. ( Dong, YQ; Fang, LD; Heng, PY; Lai, LG; Min, HW; Ping, TQ; Qing, WG; Xia, L, 2009)
"Iron overload occurs in brain after intracerebral hemorrhage (ICH)."	1.33	Deferoxamine reduces CSF free iron levels following intracerebral hemorrhage. ( Hoff, JT; Hua, Y; Keep, RF; Wan, S; Xi, G, 2006)

Research

Studies (64)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Adverse Event of Special Interest: Number of Patients With Allergic Reactions (During Infusion of Study Drug)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.56)	18.7374
1990's	1 (1.56)	18.2507
2000's	14 (21.88)	29.6817
2010's	37 (57.81)	24.3611
2020's	11 (17.19)	2.80

Authors	Studies
Foster, L	1
Robinson, L	1
Yeatts, SD	3
Conwit, RA	1
Shehadah, A	1
Lioutas, V	1
Selim, M	7
Ye, F	1
Wan, Y	1
Koduri, S	1
Holste, KG	1
Keep, RF	27
Hua, Y	26
Xi, G	31
Lin, D	1
Minyetty, M	1
Marchina, S	2
Carvalho, F	1
Heistand, E	1
Bhanu, G	1
Hasan, S	1
Kumar, S	1
Lee, KH	1
Lioutas, VA	1
Zhao, K	1
Li, J	1
Zhang, Q	3
Yang, M	1
Lai, JHC	3
Liu, J	3
Yang, T	3
Huang, J	3
Liu, Y	3
Chen, Z	4
Lee, Y	3
Leung, GKK	3
Chan, KWY	3
Sun, T	1
Zhao, YY	1
Xiao, QX	1
Wu, M	1
Luo, MY	1
Dharmalingam, P	1
Talakatta, G	1
Mitra, J	1
Wang, H	1
Derry, PJ	1
Nilewski, LG	1
McHugh, EA	1
Fabian, RH	1
Mendoza, K	1
Vasquez, V	1
Hegde, PM	1
Kakadiaris, E	1
Roy, T	1
Boldogh, I	1
Hegde, VL	1
Mitra, S	1
Tour, JM	1
Kent, TA	1
Hegde, ML	1
Farr, AC	1
Xiong, MP	1
Zhu, F	1
Zi, L	1
Yang, P	1
Wei, Y	1
Zhong, R	1
Wang, Y	1
You, C	1
Li, Y	2
Tian, M	1
Gu, Z	1
Wang, J	5
Tang, XQ	1
Xia, M	1
Li, CC	1
Guo, C	1
Ge, HF	1
Yin, Y	1
Wang, B	2
Chen, WX	1
Feng, H	3
Liu, R	1
Cao, S	1
Huang, Y	1
Garton, T	2
Xiang, J	1
Li, Q	1
Ding, Y	1
Krafft, P	1
Wan, W	1
Yan, F	1
Wu, G	2
Zhang, Y	2
Zhan, Q	1
Zhang, JH	1
Zeng, L	1
Tan, L	1
Li, H	1
Guo, J	1
Anderson, CS	1
Foster, LD	1
Moy, CS	2
Hill, MD	1
Morgenstern, LB	4
Greenberg, SM	1
James, ML	1
Singh, V	1
Clark, WM	1
Norton, C	1
Palesch, YY	2
Hu, S	3
Zhu, Q	1
Gong, Y	1
Guo, T	1
Deng, J	1
Ji, J	1
Hao, S	1
Dong, M	1
Chen-Roetling, J	2
Cai, Y	1
Lu, X	1
Regan, RF	2
Xie, Q	2
Gu, Y	3
Liu, W	2
Hatakeyama, T	3
Okauchi, M	6
Gao, C	2
Du, H	1
Strahle, J	1
Zhou, X	1
Strahle, JM	2
Bazzi, AA	1
Kilaru, H	1
Garton, HJ	2
Maher, CO	1
Muraszko, KM	1
Meng, H	1
Li, F	1
Hu, R	1
Yuan, Y	1
Gong, G	1
Ni, W	1
Yu, Y	1
Zhao, W	1
Zhu, C	1
Kong, Z	1
Xu, Y	2
Liu, G	1
Gao, X	1
Cui, HJ	1
He, HY	1
Yang, AL	1
Zhou, HJ	1
Wang, C	1
Luo, JK	1
Lin, Y	1
Tang, T	1
Garton, TP	1
He, Y	5
He, XF	1
Lan, Y	1
Liu, DX	1
Wang, Q	1
Liang, FY	1
Zeng, JS	1
Xu, GQ	1
Pei, Z	1
Kim, H	1
Edwards, NJ	1
Choi, HA	1
Chang, TR	1
Jo, KW	1
Lee, K	1
Sun, YM	1
Wang, YT	1
Jiang, L	1
Xue, MZ	1
Qing, WG	1
Dong, YQ	1
Ping, TQ	1
Lai, LG	1
Fang, LD	1
Min, HW	1
Xia, L	1
Heng, PY	1
Hoff, JT	6
Song, S	2
Wu, J	1
Bao, X	1
Huang, F	1
Wan, S	3
Zhan, R	1
Zheng, S	1
Chen, L	1
Warkentin, LM	1
Auriat, AM	2
Wowk, S	1
Colbourne, F	2
Schallert, T	3
Wu, H	1
Wu, T	1
Xu, X	1
Muraszko, K	1
Wang, L	2
Hu, H	2
Wang, MM	1
Chun, HJ	1
Kim, DW	1
Yi, HJ	1
Kim, YS	1
Kim, EH	1
Hwang, SJ	1
Jwa, CS	1
Lee, YK	1
Ryou, H	1
Yeatts, S	1
Goldstein, JN	1
Gomes, J	1
Greenberg, S	1
Schlaug, G	1
Torbey, M	1
Waldman, B	1
Palesch, Y	1
Silasi, G	1
Wei, Z	1
Paquette, R	1
Paterson, P	1
Nichol, H	1
Miao, X	1
Liu, X	1
Yue, Q	1
Qiu, N	1
Huang, W	1
Yang, J	1
Chen, X	1
Chaudhary, N	1
Gemmete, JJ	1
Thompson, BG	1
Pandey, AS	1
Nakamura, T	2
Huang, FP	1
Nemoianu, A	1
Cohen, AR	1
Martin, MB	1
Silber, JH	1
Kim, HC	1
Ohene-Frempong, K	1
Schwartz, E	1
Baker, DL	1
Manno, CS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Study of Deferoxamine Mesylate in Intracerebral Hemorrhage[NCT02175225]	Phase 2	294 participants (Actual)	Interventional	2014-10-31	Completed
Futility Study of Deferoxamine in Intracerebral Hemorrhage[NCT01662895]	Phase 2	42 participants (Actual)	Interventional	2013-03-18	Terminated (stopped due to By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol [NCT02175225)
Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248]	Phase 1/Phase 2	180 participants (Anticipated)	Interventional	2015-03-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Adverse event of special interest: anaphylaxis at any time during the study infusion (NCT02175225)
Timeframe: during the study infusion

Adverse Event of Special Interest: Number of Patients With Hypotension

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	3
Normal Saline	0

Hypotension requiring medical intervention at any time during the study infusion that could not be explained by other causes (NCT02175225)
Timeframe: during the study infusion

Adverse Event of Special Interest: Number of Patients With New Visual or Auditory Changes

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	1
Normal Saline	2

Adverse event of special interest: development of new and unexplained visual or auditory changes after initiation of the study infusion (NCT02175225)
Timeframe: after initiation of study infusion

Number of Patients With Symptomatic Cerebral Edema

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	3
Normal Saline	4

Edema accompanied by an unexplained increase of more than four points on the US National Institutes of Health Stroke Scale or a decrease of more than two points in Glasgow Coma Scale score during the first week after the intracerebral haemorrhage. (NCT02175225)
Timeframe: 7 days

Number of Subjects Experiencing Serious Adverse Events

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	9
Normal Saline	5

Number of subjects experiencing Serious adverse events at any time from randomization through day 90 (NCT02175225)
Timeframe: 90 days

Number of Subjects With Serious Adverse Events Within 7 Days

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	39
Normal Saline	49

Number of Subjects Experiencing Serious Adverse Events within 7 days of randomization (NCT02175225)
Timeframe: 7 days

Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 180 Days

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	24
Normal Saline	26

Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days

Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 Days

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	61
Normal Saline	48

The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 90 days

Proportion of Patients With Modified Rankin Scale (mRS) Score 0-3 at 180 Days

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	48
Normal Saline	47

Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days

Proportion of Patients With mRS Score 0-3 at 90 Days

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	97
Normal Saline	92

"Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome.~Although mRS 0-3 is less favorable than the primary outcome of mRS 0-2, it would still be a desirable effect in patients with ICH given that no treatments exist to reduce disability." (NCT02175225)
Timeframe: 90 days

Adverse Event of Special Interest: Number of Patients With Respiratory Compromise

Intervention	Participants (Count of Participants)
Deferoxamine Mesylate	91
Normal Saline	82

Adverse event of special interest: Respiratory compromise of any cause, including acute respiratory distress syndrome, in hospital until day 7 or discharge [whichever was earlier] (NCT02175225)
Timeframe: 7 days

Proportion of Subjects With Good Outcome (mRS 0-2) in the Early vs. Delayed Treatment Time Windows

Intervention	Participants (Count of Participants)
	All cause	Cause by acute respiratory distress syndrome
Deferoxamine Mesylate	20	2
Normal Saline	23	1

Analyses will be expanded to include an interaction between treatment and OTT window and the magnitude of the treatment effect, and corresponding confidence interval, will be estimated for each time window (<12 hours vs. >/= 12 hours) in order to explore the presence of a differential treatment effect in the OTT windows. (NCT02175225)
Timeframe: 90 days

Number of Patients Who Died During the 90-day Study Period

Intervention	Participants (Count of Participants)
	Onset to treatment time <=12 hours	Onset to treatment time >12 hours
Deferoxamine Mesylate	15	33
Normal Saline	19	28

Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days

Number of Patients With Hypotension

Number of Patients With New Visual or Auditory Changes

Number of Patients With Serious Adverse Events

Number of Subjects With Acute Respiratory Distress Syndrome

Number of Subjects With Allergic/Anaphylactic Reaction

Number of Subjects With Modified Rankin Scale (mRS) Score 0-2

Intervention	Participants (Count of Participants)
Deferoxamine	3
Normal Saline	0

Intervention	Participants (Count of Participants)
Deferoxamine	1
Normal Saline	1

Intervention	Participants (Count of Participants)
Deferoxamine	0
Normal Saline	1

Intervention	Participants (Count of Participants)
Deferoxamine	9
Normal Saline	6

Intervention	Participants (Count of Participants)
Deferoxamine	6
Normal Saline	0

Intervention	Participants (Count of Participants)
Deferoxamine	0
Normal Saline	0

"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days

Number of Subjects With mRS Score 0-3

Intervention	Participants (Count of Participants)
Deferoxamine	6
Normal Saline	10

The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days

Article	Year
Efficacy of desferrioxamine mesylate in intracerebral hematoma: a systemic review and meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:12 Topics: Animals; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Hematoma; Mesylates	2022
Deferoxamine in intracerebral hemorrhage: Systematic review and meta-analysis. Clinical neurology and neurosurgery, 2023, Volume: 227 Topics: Cerebral Hemorrhage; Deferoxamine; Hematoma; Humans; Siderophores; Stroke	2023
Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. Molecular pharmaceutics, 2021, 02-01, Volume: 18, Issue:2 Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier	2021
Challenges for intraventricular hemorrhage research and emerging therapeutic targets. Expert opinion on therapeutic targets, 2017, Volume: 21, Issue:12 Topics: Adult; Animals; Cerebral Hemorrhage; Deferoxamine; Humans; Infant; Infant, Premature; Iron Chelating	2017
Deferoxamine therapy for intracerebral hemorrhage: A systematic review. PloS one, 2018, Volume: 13, Issue:3 Topics: Cerebral Hemorrhage; Deferoxamine; Humans	2018
Deferoxamine therapy reduces brain hemin accumulation after intracerebral hemorrhage in piglets. Experimental neurology, 2019, Volume: 318 Topics: Animals; Cerebral Hemorrhage; Deferoxamine; Hemin; Hemopexin; Low Density Lipoprotein Receptor-Relat	2019
Efficacy of deferoxamine in animal models of intracerebral hemorrhage: a systematic review and stratified meta-analysis. PloS one, 2015, Volume: 10, Issue:5 Topics: Animals; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Mice; Rats; Siderophores; Swine;	2015
Treatment Strategies to Attenuate Perihematomal Edema in Patients With Intracerebral Hemorrhage. World neurosurgery, 2016, Volume: 94 Topics: Adrenal Cortex Hormones; Brain Edema; Cerebral Hemorrhage; Decompressive Craniectomy; Deferoxamine;	2016
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke, 2009, Volume: 40, Issue:3 Suppl Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob	2009
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke, 2009, Volume: 40, Issue:3 Suppl Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob	2009
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke, 2009, Volume: 40, Issue:3 Suppl Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob	2009
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke, 2009, Volume: 40, Issue:3 Suppl Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob	2009
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke, 2009, Volume: 40, Issue:3 Suppl Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob	2009
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke, 2009, Volume: 40, Issue:3 Suppl Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob	2009
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke, 2009, Volume: 40, Issue:3 Suppl Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob	2009
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke, 2009, Volume: 40, Issue:3 Suppl Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob	2009
Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke, 2009, Volume: 40, Issue:3 Suppl Topics: Animals; Cerebral Hemorrhage; Chemotherapy, Adjuvant; Deferoxamine; Disease Models, Animal; Hemoglob	2009
Deferoxamine therapy for intracerebral hemorrhage. Acta neurochirurgica. Supplement, 2008, Volume: 105 Topics: Animals; Brain Edema; Cell Death; Cerebral Hemorrhage; Deferoxamine; Humans; Neurons; Siderophores	2008

Article	Year
Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial. Stroke, 2022, Volume: 53, Issue:7 Topics: Cerebral Hemorrhage; Deferoxamine; Double-Blind Method; Humans; Medical Futility; Treatment Outcome	2022
Predicting Gastrostomy Tube Placement After Intracerebral Hemorrhage: External Validation of the GRAVo Score. Neurocritical care, 2022, Volume: 37, Issue:2 Topics: Cerebral Hemorrhage; Deferoxamine; Deglutition Disorders; Gastrostomy; Glasgow Coma Scale; Humans; M	2022
The Prognostic Roles of Perihematomal Edema and Ventricular Size in Patients with Intracerebral Hemorrhage. Neurocritical care, 2022, Volume: 37, Issue:2 Topics: Brain Edema; Cerebral Hemorrhage; Deferoxamine; Edema; Female; Humans; Prognosis	2022
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. The Lancet. Neurology, 2019, Volume: 18, Issue:5 Topics: Aged; Cerebral Hemorrhage; Deferoxamine; Double-Blind Method; Female; Humans; Infusions, Intravenous	2019
High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocritical care, 2013, Volume: 19, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cerebral Hemorrhage; Critical Care; Deferoxamine; Double	2013
High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocritical care, 2013, Volume: 19, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cerebral Hemorrhage; Critical Care; Deferoxamine; Double	2013
High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocritical care, 2013, Volume: 19, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cerebral Hemorrhage; Critical Care; Deferoxamine; Double	2013
High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocritical care, 2013, Volume: 19, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cerebral Hemorrhage; Critical Care; Deferoxamine; Double	2013
The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PloS one, 2015, Volume: 10, Issue:4 Topics: Aged; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Female; Humans; Male; Middle Aged; Tomography,	2015
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F	2011
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F	2011
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F	2011
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F	2011
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F	2011
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F	2011
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F	2011
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F	2011
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Cerebral Hemorrhage; Cohort Studies; Deferoxamine; Female; F	2011

Article	Year
Too big, too small: selecting hematoma sizes for inclusion in intracerebral hemorrhage-deferoxamine trials. Translational stroke research, 2023, Volume: 14, Issue:3 Topics: Cerebral Hemorrhage; Deferoxamine; Hematoma; Humans	2023
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging for Longitudinal Assessment of Intracerebral Hemorrhage and Deferoxamine Treatment at 3T in a Mouse Model. Stroke, 2023, Volume: 54, Issue:1 Topics: Amides; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Lipids; Magnetic Resonance Imaging; Mice;	2023
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging for Longitudinal Assessment of Intracerebral Hemorrhage and Deferoxamine Treatment at 3T in a Mouse Model. Stroke, 2023, Volume: 54, Issue:1 Topics: Amides; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Lipids; Magnetic Resonance Imaging; Mice;	2023
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging for Longitudinal Assessment of Intracerebral Hemorrhage and Deferoxamine Treatment at 3T in a Mouse Model. Stroke, 2023, Volume: 54, Issue:1 Topics: Amides; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Lipids; Magnetic Resonance Imaging; Mice;	2023
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging for Longitudinal Assessment of Intracerebral Hemorrhage and Deferoxamine Treatment at 3T in a Mouse Model. Stroke, 2023, Volume: 54, Issue:1 Topics: Amides; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Lipids; Magnetic Resonance Imaging; Mice;	2023
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging for Longitudinal Assessment of Intracerebral Hemorrhage and Deferoxamine Treatment at 3T in a Mouse Model. Stroke, 2023, Volume: 54, Issue:1 Topics: Amides; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Lipids; Magnetic Resonance Imaging; Mice;	2023
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging for Longitudinal Assessment of Intracerebral Hemorrhage and Deferoxamine Treatment at 3T in a Mouse Model. Stroke, 2023, Volume: 54, Issue:1 Topics: Amides; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Lipids; Magnetic Resonance Imaging; Mice;	2023
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging for Longitudinal Assessment of Intracerebral Hemorrhage and Deferoxamine Treatment at 3T in a Mouse Model. Stroke, 2023, Volume: 54, Issue:1 Topics: Amides; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Lipids; Magnetic Resonance Imaging; Mice;	2023
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging for Longitudinal Assessment of Intracerebral Hemorrhage and Deferoxamine Treatment at 3T in a Mouse Model. Stroke, 2023, Volume: 54, Issue:1 Topics: Amides; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Lipids; Magnetic Resonance Imaging; Mice;	2023
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging for Longitudinal Assessment of Intracerebral Hemorrhage and Deferoxamine Treatment at 3T in a Mouse Model. Stroke, 2023, Volume: 54, Issue:1 Topics: Amides; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Lipids; Magnetic Resonance Imaging; Mice;	2023
Pervasive Genomic Damage in Experimental Intracerebral Hemorrhage: Therapeutic Potential of a Mechanistic-Based Carbon Nanoparticle. ACS nano, 2020, 03-24, Volume: 14, Issue:3 Topics: Animals; Carbon; Cell Differentiation; Cells, Cultured; Cellular Senescence; Cerebral Hemorrhage; De	2020
Efficient Iron and ROS Nanoscavengers for Brain Protection after Intracerebral Hemorrhage. ACS applied materials & interfaces, 2021, Mar-03, Volume: 13, Issue:8 Topics: Animals; Antioxidants; Brain; Catechols; Cerebral Hemorrhage; Collagenases; Deferoxamine; Iron; Iron	2021
Iron chelation suppresses secondary bleeding after intracerebral hemorrhage in angiotensin II-infused mice. CNS neuroscience & therapeutics, 2021, Volume: 27, Issue:11 Topics: Angiotensin II; Animals; Cerebral Hemorrhage; Deferoxamine; Drug Combinations; Hemoglobins; Hyperten	2021
CD163 Expression in Neurons After Experimental Intracerebral Hemorrhage. Stroke, 2017, Volume: 48, Issue:5 Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; Cell Death; Cerebral Hemorr	2017
Targeting Germinal Matrix Hemorrhage-Induced Overexpression of Sodium-Coupled Bicarbonate Exchanger Reduces Posthemorrhagic Hydrocephalus Formation in Neonatal Rats. Journal of the American Heart Association, 2018, 01-31, Volume: 7, Issue:3 Topics: Animals; Animals, Newborn; Behavior, Animal; Cerebral Hemorrhage; Cerebrospinal Fluid; Chlorides; Ch	2018
Reduction of iron neurotoxicity in intracerebral haemorrhage. The Lancet. Neurology, 2019, Volume: 18, Issue:5 Topics: Cerebral Hemorrhage; Deferoxamine; Double-Blind Method; Humans; Iron; Organothiophosphates	2019
Thermo-sensitive keratin hydrogel against iron-induced brain injury after experimental intracerebral hemorrhage. International journal of pharmaceutics, 2019, Jul-20, Volume: 566 Topics: Acrylic Resins; Adsorption; Animals; Behavior, Animal; Brain; Brain Injuries; Cerebral Hemorrhage; D	2019
Role of iron in brain lipocalin 2 upregulation after intracerebral hemorrhage in rats. Brain research, 2013, Apr-10, Volume: 1505 Topics: Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Functional Laterality; Gl	2013
Hemin uptake and release by neurons and glia. Free radical research, 2014, Volume: 48, Issue:2 Topics: Animals; Cells, Cultured; Cerebral Hemorrhage; Chelating Agents; Deferoxamine; Erythrocytes; Heme Ox	2014
Deferoxamine attenuates white matter injury in a piglet intracerebral hemorrhage model. Stroke, 2014, Volume: 45, Issue:1 Topics: Animals; Blotting, Western; Body Water; Brain; Brain Chemistry; Brain Edema; Cerebral Hemorrhage; De	2014
Deferoxamine reduces neuronal death and hematoma lysis after intracerebral hemorrhage in aged rats. Translational stroke research, 2013, Volume: 4, Issue:5 Topics: Age Factors; Animals; Cell Death; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Ferriti	2013
Role of red blood cell lysis and iron in hydrocephalus after intraventricular hemorrhage. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014, Volume: 34, Issue:6 Topics: Animals; Cerebral Hemorrhage; Deferoxamine; Erythrocytes; Ferritins; Heme Oxygenase-1; Hemolysis; Hy	2014
Brain CD47 expression in a swine model of intracerebral hemorrhage. Brain research, 2014, Jul-29, Volume: 1574 Topics: Animals; Astrocytes; Brain; CD47 Antigen; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal;	2014
Role of hemoglobin and iron in hydrocephalus after neonatal intraventricular hemorrhage. Neurosurgery, 2014, Volume: 75, Issue:6 Topics: Animals; Animals, Newborn; Blotting, Western; Cerebral Hemorrhage; Deferoxamine; Disease Models, Ani	2014
Deferoxamine alleviates chronic hydrocephalus after intraventricular hemorrhage through iron chelation and Wnt1/Wnt3a inhibition. Brain research, 2015, Mar-30, Volume: 1602 Topics: Animals; Blotting, Western; Brain; Cerebral Hemorrhage; Chronic Disease; Deferoxamine; Disease Model	2015
Deferoxamine reduces intracerebral hemorrhage-induced white matter damage in aged rats. Experimental neurology, 2015, Volume: 272 Topics: Aging; Analysis of Variance; Animals; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Dos	2015
Hemoglobin-induced neuronal degeneration in the hippocampus after neonatal intraventricular hemorrhage. Brain research, 2016, Mar-15, Volume: 1635 Topics: Animals; Animals, Newborn; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cerebral Hemorrh	2016
Deferoxamine inhibits microglial activation, attenuates blood-brain barrier disruption, rescues dendritic damage, and improves spatial memory in a mouse model of microhemorrhages. Journal of neurochemistry, 2016, Volume: 138, Issue:3 Topics: Animals; Blood-Brain Barrier; Cerebral Hemorrhage; Deferoxamine; Dendrites; Disease Models, Animal;	2016
The effects of deferoxamine on inhibition for microglia activation and protection of secondary nerve injury after intracerebral hemorrhage in rats. Pakistan journal of pharmaceutical sciences, 2016, Volume: 29, Issue:3 Suppl Topics: Animals; Brain; Cell Death; Cerebral Hemorrhage; Cytoprotection; Deferoxamine; Disease Models, Anima	2016
Brain edema after intracerebral hemorrhage in rats: the role of iron overload and aquaporin 4. Journal of neurosurgery, 2009, Volume: 110, Issue:3 Topics: Animals; Aquaporin 4; Brain Chemistry; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Female; Histo	2009
Deferoxamine reduces brain swelling in a rat model of hippocampal intracerebral hemorrhage. Acta neurochirurgica. Supplement, 2008, Volume: 105 Topics: Analysis of Variance; Animals; Brain Edema; Cell Death; Cerebral Hemorrhage; Deferoxamine; Disease M	2008
Poly(ADP-ribose) polymerase activation and brain edema formation by hemoglobin after intracerebral hemorrhage in rats. Acta neurochirurgica. Supplement, 2008, Volume: 105 Topics: Animals; Brain; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Enzyme Activ	2008
Activation of c-Jun-N-terminal kinase in a rat model of intracerebral hemorrhage: the role of iron. Neuroscience research, 2009, Volume: 63, Issue:2 Topics: Analysis of Variance; Animals; Brain; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Enz	2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke, 2009, Volume: 40, Issue:5 Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;	2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke, 2009, Volume: 40, Issue:5 Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;	2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke, 2009, Volume: 40, Issue:5 Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;	2009
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke, 2009, Volume: 40, Issue:5 Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases;	2009
Minocycline attenuates iron neurotoxicity in cortical cell cultures. Biochemical and biophysical research communications, 2009, Aug-21, Volume: 386, Issue:2 Topics: Animals; Cerebral Cortex; Cerebral Hemorrhage; Cytoprotection; Deferoxamine; Iron; Iron Chelating Ag	2009
Failure of deferoxamine, an iron chelator, to improve outcome after collagenase-induced intracerebral hemorrhage in rats. Brain research, 2010, Jan-14, Volume: 1309 Topics: Animals; Behavior, Animal; Brain Edema; Brain Infarction; Cerebral Hemorrhage; Chelating Agents; Col	2010
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. Stroke, 2010, Volume: 41, Issue:2 Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo	2010
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. Stroke, 2010, Volume: 41, Issue:2 Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo	2010
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. Stroke, 2010, Volume: 41, Issue:2 Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo	2010
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. Stroke, 2010, Volume: 41, Issue:2 Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo	2010
Iron toxicity in mice with collagenase-induced intracerebral hemorrhage. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2011, Volume: 31, Issue:5 Topics: Animals; Body Weight; Cell Death; Cerebral Hemorrhage; Collagenases; Deferoxamine; Fluorescent Antib	2011
Role of iron in brain injury after intraventricular hemorrhage. Stroke, 2011, Volume: 42, Issue:2 Topics: Animals; Brain Injuries; Cerebral Hemorrhage; Deferoxamine; Hippocampus; Iron; Lateral Ventricles; M	2011
Iron accumulation and DNA damage in a pig model of intracerebral hemorrhage. Acta neurochirurgica. Supplement, 2011, Volume: 111 Topics: Animals; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; DNA Damage; Frontal Lobe; In Sit	2011
Hemoglobin expression in neurons and glia after intracerebral hemorrhage. Acta neurochirurgica. Supplement, 2011, Volume: 111 Topics: Animals; Cells, Cultured; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Embryo, Mammali	2011
Deferoxamine reduces cavity size in the brain after intracerebral hemorrhage in aged rats. Acta neurochirurgica. Supplement, 2011, Volume: 111 Topics: Aging; Animals; Antigens, Differentiation; Behavior, Animal; Brain Infarction; Cell Count; Cerebral	2011
Deferoxamine affects heat shock protein expression in heart after intracerebral hemorrhage in aged rats. Acta neurochirurgica. Supplement, 2011, Volume: 111 Topics: Aging; Analysis of Variance; Animals; Cerebral Hemorrhage; Deferoxamine; Gene Expression Regulation;	2011
Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2012, Volume: 33, Issue:2 Topics: Analysis of Variance; Animals; Atrophy; Brain Edema; CD11b Antigen; Cerebral Hemorrhage; Deferoxamin	2012
Ferric iron chelation lowers brain iron levels after intracerebral hemorrhage in rats but does not improve outcome. Experimental neurology, 2012, Volume: 234, Issue:1 Topics: Analysis of Variance; Animals; Brain; Calcium; Cerebral Hemorrhage; Deferoxamine; Disease Models, An	2012
[Deferoxamine suppresses microglia activation and protects against secondary neural injury after intracerebral hemorrhage in rats]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2012, Volume: 32, Issue:7 Topics: Animals; Cerebral Hemorrhage; Deferoxamine; Interleukin-1beta; Iron; Male; Microglia; Rats; Rats, Sp	2012
Iron--potential therapeutic target in hemorrhagic stroke. World neurosurgery, 2013, Volume: 79, Issue:1 Topics: Cerebral Hemorrhage; Deferoxamine; Humans; Iron; Iron Chelating Agents; Nerve Degeneration; Stroke	2013
Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Journal of neurosurgery, 2004, Volume: 100, Issue:4 Topics: Animals; Blotting, Western; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal;	2004
Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Neurosurgical focus, 2003, Oct-15, Volume: 15, Issue:4 Topics: Animals; Basal Ganglia; Brain Edema; Cerebral Hemorrhage; Chelation Therapy; Deferoxamine; DNA-(Apur	2003
Deferoxamine reduces CSF free iron levels following intracerebral hemorrhage. Acta neurochirurgica. Supplement, 2006, Volume: 96 Topics: Animals; Behavior, Animal; Brain; Cerebral Hemorrhage; Deferoxamine; Iron; Iron Chelating Agents; Ma	2006
A new hippocampal model for examining intracerebral hemorrhage-related neuronal death: effects of deferoxamine on hemoglobin-induced neuronal death. Stroke, 2007, Volume: 38, Issue:10 Topics: Animals; Cell Death; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Hemoglobins; Hippoca	2007
Autophagy after experimental intracerebral hemorrhage. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2008, Volume: 28, Issue:5 Topics: Animals; Autophagy; Basal Ganglia; Blotting, Western; Cathepsin D; Cerebral Hemorrhage; Deferoxamine	2008
Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. Journal of neurosurgery, 2002, Volume: 96, Issue:2 Topics: Animals; Bilirubin; Brain; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; F	2002
A modified transfusion program for prevention of stroke in sickle cell disease. Blood, 1992, Apr-01, Volume: 79, Issue:7 Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Cerebral Hemorrhage; Cerebrovascular Diso	1992
Rapid excretion of gallium-67 isotope in an iron-overloaded patient receiving high-dose intravenous deferoxamine. American journal of hematology, 1988, Volume: 29, Issue:4 Topics: Adult; Cerebral Hemorrhage; Cerebral Ventricles; Deferoxamine; Drug Administration Schedule; Fever;	1988

deferoxamine and Cerebral Hemorrhage